Department of Molecular Genetics, Madras Diabetes Research Foundation, ICMR Advanced Centre for Genomics of Type 2 Diabetes, Affiliated to University of Madras, Chennai, India.
Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention & Control, IDF Centre of Education, Chennai, India.
Pediatr Diabetes. 2021 Feb;22(1):82-92. doi: 10.1111/pedi.13109. Epub 2020 Sep 15.
There are very few reports pertaining to Indian patients with neonatal diabetes mellitus (NDM). Activating or gain of function mutations of K channel genes namely KCNJ11 and ABCC8 are most predominant cause of permanent neonatal diabetes mellitus (PNDM).
To identify the genotype-phenotype correlation of K channel gene defects in a large series of (n = 181) Indian PNDM patients.
Direct sequencing of all exons of KCNJ11 and ABCC8 genes in all 181 patients with PNDM were performed. Clinical and biochemical data were collected.
We have identified the molecular basis of K -NDM in 39 out of 181 patients (22%). Of these, 20 had KCNJ11 mutations and 19 had ABCC8 mutations, thus comprising 51% of KCNJ11 and 49% of ABCC8. There were four novel mutations (D1128Tfs*16, Y1287C, S1422T, and H1537R) in ABCC8 gene. Three patients with KCNJ11 mutations had developmental delay with DEND syndrome. In patients with ABCC8 mutations developmental delay was seen in seven out of 19 (36.8%). Of this, three patients (15.7%) had DEND phenotype and four (21%) had iDEND. Of the 39 patients, 33 (84%) patients were shifted to sulfonylurea therapy (glibenclamide). Of this, 19(57.5%) patients harbored KCNJ11 mutations and 14(42.1%) ABCC8 mutations.
This is the first largest study in NDM patients in India demonstrating the importance of K channel gene mutation screening in PNDM and efficacy of glibenclamide for Indian patients with K -PNDM. The success rate of transfer is more in patients with KCNJ11 mutations compared with those with ABCC8 mutations.
关于印度新生儿糖尿病(NDM)患者的报告非常少。K 通道基因突变(即 KCNJ11 和 ABCC8)是导致永久性新生儿糖尿病(PNDM)的最主要原因。
在一组较大的(n=181)印度 PNDM 患者中,确定 K 通道基因突变的基因型-表型相关性。
对 181 例 PNDM 患者的 KCNJ11 和 ABCC8 基因所有外显子进行直接测序。收集临床和生化数据。
我们在 181 例 PNDM 患者中的 39 例(22%)中确定了 K-NDM 的分子基础。其中,20 例有 KCNJ11 突变,19 例有 ABCC8 突变,因此 KCNJ11 占 51%,ABCC8 占 49%。ABCC8 基因中有四个新突变(D1128Tfs*16、Y1287C、S1422T 和 H1537R)。3 例 KCNJ11 突变患者有发育迟缓伴 DEND 综合征。ABCC8 突变患者中有 7 例(36.8%)发育迟缓。其中,3 例(15.7%)有 DEND 表型,4 例(21%)有 iDEND。在 39 例患者中,33 例(84%)患者转为磺脲类药物治疗(格列本脲)。其中,19 例(57.5%)患者有 KCNJ11 突变,14 例(42.1%)有 ABCC8 突变。
这是印度 NDM 患者中最大的 K 通道基因突变筛查研究之一,表明在 PNDM 中进行 K 通道基因突变筛查的重要性以及格列本脲对印度 K-PNDM 患者的疗效。与 ABCC8 突变患者相比,KCNJ11 突变患者的转移成功率更高。